Antibody kinetics and clinical course of COVID-19 a prospective observational study

Research output: Contribution to journalArticle

Standard

Antibody kinetics and clinical course of COVID-19 a prospective observational study. / Bläckberg, Anna; Fernström, Nils; Sarbrant, Emma; Rasmussen, Magnus; Sunnerhagen, Torgny.

In: PLoS ONE, Vol. 16, No. 3 March, e0248918, 2021.

Research output: Contribution to journalArticle

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - Antibody kinetics and clinical course of COVID-19 a prospective observational study

AU - Bläckberg, Anna

AU - Fernström, Nils

AU - Sarbrant, Emma

AU - Rasmussen, Magnus

AU - Sunnerhagen, Torgny

PY - 2021

Y1 - 2021

N2 - Background Serological response and association to clinical manifestation is important for understanding the pathogenesis of COVID-19. Materials and methods A prospective observational study was conducted where antibody responses of IgG and IgA towards SARS-CoV-2 spike protein were studied over time in patients with COVID-19. Possible associations between antibody titers and outcome were analyzed. Results Forty patients with COVID-19, hospitalized at Skåne University hospital, Sweden, between April and June 2020 were included. IgG antibody responses were detected for all patients with the highest levels four weeks after COVID-19 diagnosis. Levels of IgA were generally higher at diagnosis and decreased towards baseline 4 weeks after confirmed COVID-19. Patients with severe COVID-19 had higher levels of antibodies directed against SARS-CoV- 2 spike protein compared with patients with mild disease. Conclusion IgG and IgA antibodies towards the spike protein follow different kinetics during COVID-19 and patients with severe disease develop higher antibody levels.

AB - Background Serological response and association to clinical manifestation is important for understanding the pathogenesis of COVID-19. Materials and methods A prospective observational study was conducted where antibody responses of IgG and IgA towards SARS-CoV-2 spike protein were studied over time in patients with COVID-19. Possible associations between antibody titers and outcome were analyzed. Results Forty patients with COVID-19, hospitalized at Skåne University hospital, Sweden, between April and June 2020 were included. IgG antibody responses were detected for all patients with the highest levels four weeks after COVID-19 diagnosis. Levels of IgA were generally higher at diagnosis and decreased towards baseline 4 weeks after confirmed COVID-19. Patients with severe COVID-19 had higher levels of antibodies directed against SARS-CoV- 2 spike protein compared with patients with mild disease. Conclusion IgG and IgA antibodies towards the spike protein follow different kinetics during COVID-19 and patients with severe disease develop higher antibody levels.

U2 - 10.1371/journal.pone.0248918

DO - 10.1371/journal.pone.0248918

M3 - Article

C2 - 33750984

AN - SCOPUS:85103152145

VL - 16

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 3 March

M1 - e0248918

ER -